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Objective. To determine serum levels of CCL13 and its clinical associations in 
patients with systemic sclerosis (SSc). 
Methods. Serum CCL13 levels were examined by ELISA in 80 patients with SSc, 20 
patients with systemic lupus erythematosus, 20 patients with dermatomyositis, 29 
patients with atopic dermatitis, and 50 healthy individuals. 
Results. Serum CCL13 levels were elevated in SSc patients (81.3 ± 55.8 pg/ml) 
compared to healthy controls (15.0 ± 9.9 pg/ml; p<0.001) and patients with systemic 
lupus erythematosus (22.0 ± 6.9 pg/ml; p<0.001), dermatomyositis (24.4 ± 36.1 
pg/ml; p<0.001), or atopic dermatitis (18.0 ± 6.4 pg/ml; p<0.001). Among SSc 
patients, there were no differences in serum CCL13 levels between limited cutaneous 
SSc and diffuse cutaneous SSc. In the longitudinal study, CCL13 levels were 
generally unchanged during the followup. 
Conclusion. Serum CCL13 was specifically increased in patients with SSc, but not in 
patients with systemic lupus erythematosus, dermatomyositis, atopic dermatitis, or 
healthy controls. CCL13 could be a promising serological marker for SSc. 
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Introduction 
Systemic sclerosis (SSc) is a generalized connective tissue disorder characterized by 
sclerotic and vascular changes in the skin and various internal organs. A variety of 
immunological abnormalities of T and B lymphocytes have been detected in SSc1. 
Autoantibodies are positive in >90% of patients, and these autoantibodies react to 
various intracellular components, such as DNA topoisomerase I, centromere, RNA 
polymerases, U1RNP, and U3RNP2. Moreover, hyper--globulinemia and polyclonal 
B cell hyperactivity are detected in patients with SSc3,4. In addition, many previous 
studies have suggested that some cytokines or growth factors regulate the induction of 
SSc by stimulating the synthesis of extracellular matrix components, injuring the 
endothelial cells, and modulating the function of leucocytes1,5. In early skin lesions of 
SSc patients, mononuclear cell infiltration is first seen around small vessels in the 
dermis4,6. Furthermore, the degree of mononuclear cell infiltration correlates with 
both the degree and progression of skin thickening7. Thus, immunological 
abnormalities and inflammatory cell infiltration play a crucial role in initiating and 
developing fibrosis in SSc. 
 Chemokines are the most potent molecules that regulate the migration and 
recruitment of specific leukocytes. CCL13 (monocyte chemoattract protein-4) is a 
member of the CC chemokine family and directs the migration of 
monocytes/macrophages, T-lymphocytes, and eosinophils through its functional 
ligands CC chemokine receptor (CCR) 2 and 38,9. CCL13 is also highly expressed in 
cartilage from patients with rheumatoid arthritis10. Furthermore, CCL13 concentration 
is increased in sera from patients with rheumatoid arthritis10. Therefore, we suggest 
that CCL13 may have some role in the pathogenesis of SSc. In this study, we 
examined serum levels of CCL13 in patients with SSc, and related these results to 
clinical features. In addition, we undertook a retrospective longitudinal study of 




Materials and Methods 
Patients 
Serum samples were obtained from 80 Japanese patients with SSc (68 females and 12 
males). All patients fulfilled criteria for SSc proposed by the American College of 
Rheumatology (ACR)11. These patients were grouped according to the classification 
system12 as follows: 32 patients had limited cutaneous SSc (lSSc) and 48 had diffuse 
cutaneous SSc (dSSc). Anti-topoisomerase I antibodies (Abs) were positive in 34 
patients; anticentromere Abs in 27; anti-RNA polymerase I and III Abs in six; 
anti-U1RNP Abs in three; anti-U3RNP Abs in one; anti-Th/To Abs in one; and eight 
were negative. These patients were aged 10-74 years (mean age 50). The mean 
disease duration was 4.3 ± 5.6 (range: 0.2-29) years. At the first visit, seven patients 
had been treated with low dose steroids (prednisolone 5 to 20 mg/day) and five with 
low dose D-penicillamine (100 to 500 mg/day). None of the patients had received 
immunosuppressive treatment. 
Twenty patients with systemic lupus erythematosus (SLE) who fulfilled the 
ACR criteria13, 20 with dermatomyositis (DM) who fulfilled the criteria of Bohan and 
Peter14, and 29 patients with atopic dermatitis (AD) who fulfilled the criteria proposed 
by Hanifin and Rajka15 acted as disease controls. Fifty age- and sex-matched healthy 
Japanese individuals were used as healthy controls. 
In a retrospective longitudinal study, we analyzed 68 serum samples from 24 
of 80 patients with SSc who could have been followed longitudinally (22 women and 
two men). There was no bias in patient selection. The mean followup period was 3.9 ± 
1.8 (1.3-7.6) years with 2.8 (2-5) time-points. The mean disease duration was 3.9 ± 
5.5 (0.4-13.3) years. Ten patients had dSSc and 14 had lSSc; Anti-topo I Abs were 
positive in nine patients (all dSSc); and anticentromere Abs in 15 (one dSSc, 14 lSSc).  
These patients were aged 34-72 years (mean age 56). 
Fresh venous blood samples were centrifuged shortly after clot formation. 
All samples were stored at –70°C before use. 
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Clinical assessment 
Complete medical histories, physical examinations, and laboratory tests were 
conducted for all patients at their first visit, with evaluations especially for pulmonary 
fibrosis during follow-up visits. Organ system involvement was defined as 
described16,17: lung = bibasilar fibrosis on chest radiography and high-resolution 
computed tomography; esophagus = hypomotility shown by barium radiography; 
heart = pericarditis, congestive heart failure, or arrhythmias requiring treatment; 
kidney = malignant hypertension and rapidly progressive renal failure with no other 
explanation; and muscle = proximal muscle weakness and elevated serum creatine 
kinase. Pulmonary fibrosis was defined as bibasilar interstitial fibrosis on chest high 
resolution computed tomography. In addition, pulmonary function test, including vital 
capacity (VC) and diffusion capacity for carbon monoxide (DLco), was also evaluated 
to examine the severity of pulmonary fibrosis. When the DLco and VC were <75% 
and <80%, respectively, of the predicted normal values, they were considered to be 
abnormal. Patients with SSc who were smokers or who had other respiratory disorders 
that could have affected %DLco or %VC were excluded from this study. The 
modified Rodnan total skin thickness score (TSS) was measured by summing the skin 
thickness measurements, and determined by palpation on a 0-3 scale in 17 body 
areas18. The protocol was approved by the Nagasaki University Graduate School of 
Biomedicinal Sciences and Nagasaki University Hospital, and informed consent was 
obtained from all patients. 
 
Detection of serum CCL13 
Serum CCL13 levels were measured with specific enzyme-linked immunosorbent 
assay (ELISA) kits (R&D Systems, Minneapolis, MN, USA), according to the 
manufacturer’s protocol. This ELISA system can detect all circulating CCL13 





Skin biopsy samples were taken from the dorsal aspect of the mid-forearm of 6 female 
patients with SSc (3 dSSc and 3 lSSc) and 6 healthy female volunteers. CCL13 
expression in the skin tissue was determined using goat IgG anti-human CCL13 
polyclonal Ab (R&D Systems). Frozen dermal tissues were air-dried and 
subsequently fixed in cold acetone. The tissue sections were incubated overnight with 
anti-CCL13 polyclonal Ab at 4°C, and then treated with biotinylated rabbit anti-goat 
IgG Ab for 45 min at room temperature, following by incubation with 
avidin-biotin-peroxidase complex for 30 min. Sections were incubated with 
diaminobenzidine tetrahydrochloride substrate solution for 5 min, counterstained with 
methyl green, and embedded in balsam. Isotype-matched control polyclonal Ab was 
used as a negative control. 
 
Statistical Analysis 
The Mann-Whitney U-test was used to compare CCL13 levels, Fisher’s exact 
probability test to compare frequencies, and Bonferroni’s test used for multiple 
comparisons. Spearman’s rank correlation coefficient was used to examine the 
relationship between two continuous variables. A probability (p) values less than 0.05 
were considered statistically significant.  
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Results 
Serum CCL13 levels were elevated in patients with SSc 
Serum CCL13 levels at the first visit were significantly higher in patients with SSc 
(81.3 ± 55.8 pg/ml) than healthy controls (15.0 ± 9.9 pg/ml; p<0.001; Fig. 1), patients 
with SLE (22.0 ± 6.9 pg/ml; p<0.001), patients with DM (24.4 ± 36.1 pg/ml; p<0.001), 
and patients with AD (18.0 ± 6.4 pg/ml; p<0.001). Concerning SSc subgroups, 
CCL13 levels in both patients with dSSc (82.2 ± 53.0 pg/ml) and those with lSSc 
(80.0 ± 60.5 pg/ml) were increased compared with those in healthy controls (p<0.001 
and p<0.01, respectively). There was no significant difference in serum CCL13 levels 
between patients with dSSc and lSSc. Thus, serum CCL13 concentrations were 
increased in patients with SSc, but not in patients with SLE, DM, AD, or healthy 
controls. 
 Clinical and laboratory parameters obtained at the first evaluation were 
compared between SSc patients with elevated CCL13 levels and those with normal 
CCL13 levels. Values higher than the mean + 2 SD (34.7 pg/ml) of the control serum 
samples were considered to be elevated in this study. Serum CCL13 levels did not 
correlate with clinical features and laboratory data (Table I). 
 Seventy-six of 80 patients with SSc (46 dSSc, 30 lSSc) exhibited elevated 
CCL13 levels, while one of 50 healthy controls, one of 20 patients with DM, and one 
of 29 patients with AD showed increased CCL13 levels (Fig. 1). None of 20 patients 
with SLE had increased CCL13 concentrations. 
 
Immunohistochemical expression of CCL13 in the skin of patients with SSc. 
Whether CCL13 expression was augmented in the skin of patients with SSc was 
assessed by immunohistochemical analysis. Patients with SSc had remarkably higher 
expression of CCL13 in the dermis compared with healthy controls (Fig. 2). Further, 
fibroblasts in the dermis of patients with SSc exhibited strong CCL13 expression. 




Longitudinal study of serum CCL13 levels 
To assess changes in serum CCL13 levels over time, 68 serum samples from 24 
patients with SSc (10 dSSc and 14 lSSc patients) were analyzed retrospectively. None 
of these patients had received any treatment at their first visit. Twenty-two of 24 SSc 
patients exhibited elevated CCL13 levels at their first visit. Serum CCL13 levels in 
seven of the 22 SSc patients were decreasing during the followup of 2.9 ± 1.7 
(1.3-7.0) years (Fig. 3a). Their disease duration at the initial visit was 4.0 ± 4.6 
(0.5-13.0) years. Serum CCL13 levels at the final evaluation were within normal 
range in one of these patients. During the followup, four of the seven patients 
exhibited subacute deterioration of interstitial pneumonitis, and three of the four 
patients received cyclophosphamide pulse therapy (Cases 1-3), and one had steroid 
pulse therapy (Case 4) for the pulmonary involvement. Treatment with low dose 
steroids alone was started in two of the remaining four patients. 
Serum CCL13 levels in 15 of the SSc patients with high CCL13 levels at first 
visit remained high during the followup of 4.0 ± 1.8 (1.8-7.6) years (Fig. 3b). Their 
disease duration was 4.8 ± 6.2 (0.4-13.3) years. After the initial visit, treatment with 
low dose steroids alone was started in three of the 15 patients. 
Finally, two out of 24 SSc patients examined in this study exhibited normal 
CCL13 levels at the first visit that stayed within normal range throughout the 
followup period of 3.9 ± 1.7 (2.5-4.7) years (Fig. 3c). Their disease duration was 4.0 ± 
4.6 (0.5-13.0) years. None of these SSc patients had received D-penicillamine or 
steroids during the followup period. Thus, CCL13 levels were generally unchanged 
during the followup period, although steroid or immunosuppressive therapy might 





This is the first report of elevated serum CCL13 levels in patients with SSc. We 
assessed patients with SSc, SLE, DM, and AD, but the CCL13 levels were increased 
only in the patients with SSc (Fig. 1). The CCL13 levels were raised not only in dSSc, 
but also in lSSc. Elevated CCL13 levels were not associated with clinical features and 
laboratory data (Table I). Furthermore, the CCL13 levels were generally unchanged 
during the followup period, although steroid or immunosuppressive therapy might 
decrease CCL13 concentrations (Fig. 3). Thus, serum CCL13 would be a promising 
diagnostic marker for SSc. 
 Although the pathogenesis of SSc remains unclear, it has recently been 
proposed that oxidative stress may play an important role in the development of SSc19. 
Ischemia and reperfusion injury following Raynaud’s phenomenon can generate 
reactive oxygen species (ROS) that may result in vascular endothelial damage20,21. 
ROS also stimulate fibroblast proliferation, leading to fibrosis22. Interestingly, CCL13 
induces the production of ROS23. In this study, CCL13 expression in dermal 
fibroblasts was similarly augmented in patients with dSSc and lSSc compared with 
healthy controls (Fig. 2). Serum CCL13 levels were equally elevated in patients with 
dSSc and lSSc (Fig. 1). Therefere, CCL13 production is likely to be augmented in 
patients with SSc regardless of the disease severity. Consistently, enhanced oxidative 
stress in both dSSc and lSSc has been demonstrated since some biomarkers of 
oxidative stress, including heat shock protein 70, N-(hexanoyl)lysine, are increased 
in sera from patients with SSc24,25. Thus, CCL13 may play a key role in the 
pathogenesis of SSc by producing ROS. 
 Cyclophosphamide and steroid pulse therapy for the interstitial pneumonia 
seemed to decrease CCL13 levels in sera from patients with SSc (Fig. 3a). 
Cyclophosphamide treatment improves lung fibrosis and skin thicking associated with 
SSc26. Therefore, strong immunosuppression may alter systemic inflammatory 
condition, leading to the improvement of fibrosis to some extent. However, CCL13 
expression in bronchoalveolar lavage and lung specimen is substantially enhanced in 
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patients with tuberculosis and chronic bronchitis27, suggesting that nonspecific 
inflammation may also induce CCL13 expression. Further studies are needed to 
address the role of CCL13 in the pathogenesis of SSc. Nonetheless, the measurement 
of CCL13 in patients who are suspected of SSc may offer an important approach in 
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Figure Legends 
Fig. 1 Serum levels of CCL13 in patients with SSc, dSSc, lSSc, SLE, DM, AD, and 
normal controls (Control). Serum CCL13 levels were determined by a specific ELISA. 
Bars indicate the mean value in each group. The broken line indicates the cut-off 
value (mean + 2 SD of the normal control samples). 
Fig. 2 Representative CCL13 expression in normal skin tissues (a) and lesional skin 
tissues from patients with SSc (b). Original magnification x250. 
Fig. 3 Serial changes of serum CCL13 levels during the followup period in SSc 
patients with elevated CCL13 levels at their first visit but decreasing during followup 
(a), SSc patients with elevated CCL13 levels at their first visit and stable during 
followup (b), and SSc patients with normal CCL13 levels at first visit (c). Serum 
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Table 1. Clinical and laboratory of in patients with SSc showing elevated serum CCL13 
levels. 
 Elevated CCL13 Normal CCL13 
 n=76 n=4 
 Age at onset, yrs, mean ± SD 47 ± 15 37 ± 14 
 Male : Female 11: 65 1: 3 
 Duration, yrs, mean ± SD 4.2 ± 5.7 4.9 ± 3.7 
 TSS, points, mean ± SD 13.4 ± 9.3 12.3 ± 7.9 
 Clinical features %   
   dSSc 61 50 
   lSSc 39 50 
   Pitting scars/ulcers 30 50 
   Contracture of phalanges 41 0 
   Diffuse pigmentation 46 75 
   Telangiectasia 38 75 
 Organ involvement %   
   Pulmonary fibrosis 58 25 
     Decreased %VC 23 25 
     Decreased %DLco 60 50 
   Pulmonary hypertension 15 0 
   Esophagus 69 50 
   Heart 11 0 
   Kidney 2 0 
   Joint 14 50 
   Muscle 11 0 
 Laboratory findings %   
   Anti-topoisomerase I Ab 42 25 
   Anticentromere Ab 37 25 
   Increased IgG 25 25 
   Elevated ESR 47 25 
   Elevated CRP 17 25 
   
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.  
Unless noted otherwise, values are percentages. Patient numbers are given in parentheses.  
* p < 0.05, ** p < 0.01 versus SSc patients with normal serum CCL13 levels. 
